244 related articles for article (PubMed ID: 20869408)
1. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulant efficacy of solid oral formulations containing a new heparin derivative.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Moon HT; Kim CY; Byun Y
Mol Pharm; 2010 Jun; 7(3):836-43. PubMed ID: 20349950
[TBL] [Abstract][Full Text] [Related]
3. Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate.
Lee DY; Kim SK; Kim YS; Son DH; Nam JH; Kim IS; Park RW; Kim SY; Byun Y
J Control Release; 2007 Apr; 118(3):310-7. PubMed ID: 17291620
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Lim KM; Moon HT; Kim CY; Byun Y
Thromb Haemost; 2011 Jun; 105(6):1060-71. PubMed ID: 21437357
[TBL] [Abstract][Full Text] [Related]
5. Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis.
Hwang SR; Seo DH; Al-Hilal TA; Jeon OC; Kang JH; Kim SH; Kim HS; Chang YT; Kang YM; Yang VC; Byun Y
J Control Release; 2012 Nov; 163(3):374-84. PubMed ID: 23041275
[TBL] [Abstract][Full Text] [Related]
6. Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis.
Lee DY; Park K; Kim SK; Park RW; Kwon IC; Kim SY; Byun Y
Clin Cancer Res; 2008 May; 14(9):2841-9. PubMed ID: 18451252
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
[TBL] [Abstract][Full Text] [Related]
8. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
Kim SK; Lee DY; Kim CY; Nam JH; Moon HT; Byun Y
J Control Release; 2007 Nov; 123(2):155-63. PubMed ID: 17884230
[TBL] [Abstract][Full Text] [Related]
9. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation.
Kim SK; Vaishali B; Lee E; Lee S; Lee YK; Kumar TS; Moon HT; Byun Y
Thromb Res; 2006; 117(4):419-27. PubMed ID: 15913716
[TBL] [Abstract][Full Text] [Related]
10. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates.
Kim SK; Lee EH; Vaishali B; Lee S; Lee YK; Kim CY; Moon HT; Byun Y
J Control Release; 2005 Jun; 105(1-2):32-42. PubMed ID: 15925422
[TBL] [Abstract][Full Text] [Related]
11. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor.
Lee E; Kim YS; Bae SM; Kim SK; Jin S; Chung SW; Lee M; Moon HT; Jeon OC; Park RW; Kim IS; Byun Y; Kim SY
Int J Cancer; 2009 Jun; 124(12):2755-65. PubMed ID: 19243020
[TBL] [Abstract][Full Text] [Related]
12. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
Kim SK; Lee DY; Lee E; Lee YK; Kim CY; Moon HT; Byun Y
J Control Release; 2007 Jul; 120(1-2):4-10. PubMed ID: 17490773
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells.
Lee DY; Lee SW; Kim SK; Lee M; Chang HW; Moon HT; Byun Y; Kim SY
Pharm Res; 2009 Dec; 26(12):2667-76. PubMed ID: 19830530
[TBL] [Abstract][Full Text] [Related]
14. Prevention effect of orally active heparin derivative on deep vein thrombosis.
Kim SK; Lee DY; Kim CY; Moon HT; Byun Y
Thromb Haemost; 2006 Aug; 96(2):149-53. PubMed ID: 16894457
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic activity and antitumor efficacy of amphiphilic twin drug from ursolic acid and low molecular weight heparin.
Cheng W; Dahmani FZ; Zhang J; Xiong H; Wu Y; Yin L; Zhou J; Yao J
Nanotechnology; 2017 Feb; 28(7):075102. PubMed ID: 28091396
[TBL] [Abstract][Full Text] [Related]
16. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.
Alam F; Al-Hilal TA; Chung SW; Seo D; Mahmud F; Kim HS; Kim SY; Byun Y
Biomaterials; 2014 Aug; 35(24):6543-52. PubMed ID: 24816287
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical conjugation with deoxycholic acid and dimethylsulfoxide for heparin oral delivery.
Kim SK; Huh J; Kim SY; Byun Y; Lee DY; Moon HT
Bioconjug Chem; 2011 Jul; 22(7):1451-8. PubMed ID: 21627301
[TBL] [Abstract][Full Text] [Related]
18. Preparation of sodium deoxycholate (DOC) conjugated heparin derivatives for inhibition of angiogenesis and cancer cell growth.
Cho KJ; Moon HT; Park GE; Jeon OC; Byun Y; Lee YK
Bioconjug Chem; 2008 Jul; 19(7):1346-51. PubMed ID: 18588324
[TBL] [Abstract][Full Text] [Related]
19. Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor.
Adulnirath A; Chung SW; Park J; Hwang SR; Kim JY; Yang VC; Kim SY; Moon HT; Byun Y
J Control Release; 2012 Nov; 164(1):8-16. PubMed ID: 23063549
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
